Improving Prediction & Translation of ADC Toxicities to Drive More Tolerable ADCs Successfully Into & Through Clinical Development
Welcome to the 3rd ADC Toxicity Summit
Preventing, Predicting and Mitigating ADC Toxicities
Toxicities continue to pose the most significant challenge in the progression of antibody-drug conjugates to the clinic, and with increasing companies entering into the ADC space and tackling toxicity, there is ever-increasing target and indication-competition. Considering the significant clinical setbacks witnessed in 2024, the demand to better understand the translatability of toxicities and develop more tolerable ADCs for achieving future clinical triumphs only grows stronger.
By addressing translational challenges and tackling off-target toxicities, the 2nd ADC Toxicity Summit returned at an imperative time to allow you to prevent, predict and mitigate toxicities to design and develop ADCs with a wider therapeutic index and progress them to the clinic.
Brand New Agenda
Toxicities continue to pose the most significant challenge in the progression of antibody-drug conjugates to the clinic, and with increasing companies entering into the ADC space and tackling toxicity, there is ever-increasing target and indication-competition. Considering the significant clinical setbacks witnessed in 2024, the demand to better understand the translatability of toxicities and develop more tolerable ADCs for achieving future clinical triumphs only grows stronger.
World-Class Speaker Faculty Includes:
Previous Attendees Include:
What Your Peers Have to Say:
2025 Event Partners:
